Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04533373
Other study ID # IRB00167074
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2020
Est. completion date December 31, 2025

Study information

Verified date February 2024
Source Johns Hopkins University
Contact Rafael Tinogco
Phone 443-287-6012
Email rtiongc1@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Common goals of breast reconstruction include obtaining satisfactory breast symmetry, softness, and appropriate size and shape. Advances in surgical techniques have prompted a new goal: achieving breast sensation after reconstructive surgery. This desire has led the surgical community to investigate operative techniques for achieving this goal. However, few studies have examined the effectiveness of breast sensory restoration. Sensory nerves are nerves responsible for sensation from skin. When a sensory nerve is cut, sensation is lost to the area supplied by the nerve. In the case of Breast reconstruction this involves the nerves supplying the skin overlying breast(s). 'Neurotization' refers to regeneration of the nerve after it has been cut. This means that the cut nerve is being repaired in order to restore its function. In Neurotization this repair is carried out using a new "source". In this case, the investigators want to restore function of the nerves that supply the skin overlying the breast(s). The investigators will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall. The Avance® Nerve graft is a nerve graft material that has been produced by Axogen, Inc. The graft is made by processing donated human nerves. This graft is used during neurotization to bridge the gap and join the nerve from the abdominal tissue to the nerve in the chest wall. The use of the graft helps the body to attach these 2 nerves and improves nerve repair. When neurotization is done without the nerve graft there is a possibility that the surgeon may require extra nerve material to join the 2 nerves. Traditionally, in this case the surgeon would have to obtain a separate donor nerve from another part of the patient's body. This technique carries the risk of complications to part of the body that the separate donor nerve was obtained from - loss of sensation, infection or neuroma formation (an abnormal growth of nerve tissue that can cause pain, burning or tingling sensation, numbness). The Avance nerve graft avoids the need for the additional donor nerve and the possible complications associated with it. The Avance® Nerve Graft is currently being used in some women during breast reconstruction surgery, however the effectiveness of this procedure in improving the restoration of sensation has not been proven. Women undergoing reconstruction of one breast and at the same time using the women's own tissue as part of standard clinical care, may join.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
DIEP Flap Neurotization
We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.

Locations

Country Name City State
United States Johns Hopkins Hospital Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Axogen Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 12-month Breast sensation as assessed by the AcroValTM device Breast sensation, measured in cutaneous thresholds using the AcroValTM device. 12-months after DIEP Flap neurotization
Secondary Breast sensation at 6 months as assessed by the AcroValTM device Breast sensation, measured in cutaneous thresholds using the AcroValTM device. 6 months after DIEP flap breast reconstruction
Secondary Breast sensation at 18 months as assessed by the AcroValTM device Breast sensation, measured in cutaneous thresholds using the AcroValTM device. 18 months after DIEP flap breast reconstruction
Secondary Breast sensation at 24 months as assessed by the AcroValTM device Breast sensation, measured in cutaneous thresholds using the AcroValTM device. 24 months after DIEP flap breast reconstruction
Secondary Breast-specific health-related quality of life using the Breast-Q® The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:
i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome
and 3 well-being sub-domains:
i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being
Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.
6 months after DIEP flap breast reconstruction
Secondary Breast-specific health-related quality of life using the Breast-Q® The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:
i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome
and 3 well-being sub-domains:
i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being
Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.
12 months after DIEP flap breast reconstruction
Secondary Breast-specific health-related quality of life using the Breast-Q® The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:
i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome
and 3 well-being sub-domains:
i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being
Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.
18 months after DIEP flap breast reconstruction
Secondary Breast-specific health-related quality of life using the Breast-Q® The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:
i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome
and 3 well-being sub-domains:
i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being
Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.
24 months after DIEP flap breast reconstruction
Secondary General health-related quality of life using the SF-12 The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life. 6 months after DIEP flap breast reconstruction
Secondary General health-related quality of life using the SF-12 The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life. 12 months after DIEP flap breast reconstruction
Secondary General health-related quality of life using the SF-12 The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life. 18 months after DIEP flap breast reconstruction
Secondary General health-related quality of life using the SF-12 The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life. 24 months after DIEP flap breast reconstruction
Secondary Change in breast sensation as assessed by the AcroValTM device Change in breast sensation from baseline, measured in cutaneous thresholds using the AcroValTM device. Baseline, 6, 12, 18 and 24 months after DIEP flap breast reconstruction
Secondary Change in breast-specific health-related quality of life using the Breast-Q® The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:
i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome
and 3 well-being sub-domains:
i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being
Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.
Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
Secondary Change in general health-related quality of life using the SF-12 The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life. Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A